Sialic Acid-Siglec Axis as Molecular Checkpoints Targeting of Immune System: Smart Players in Pathology and Conventional Therapy
Round 1
Reviewer 1 Report
This review focuses on some examples of the potential role of the sialic acid-Siglec checkpoint in pathological states and related conventional therapies. I think that this subject will attract wide range of readers. I am happy to tell you that this review should be accepted for publication.
Author Response
We thank the reviewers the reviewer for comments and suggestions. It was an honour to know the positive opinion about this manuscript.
Reviewer 2 Report
The Authors have investigated the the role for sialoglycans at various clinical stages immune-based pathologies and their frequently altered expression, as well as recognition by individual sialic acid-binding immunoglobulin-like lectins (Siglecs), can be related to the increased progression of 50 the pathological processes. The Authors, focuses on the engagement of sialic 51 acid-Siglec axis in some pathophysiological processes and its importance in routine clinical practice
Minor revision:
- The Authors should include improve the quality of the Figure 1.0
- The Authors should include a small section on the methodological approach detect and follow sialoglycans if is possible.
- The Authors should better elaborate the phrases on row 392 “Given the high cellular and molecular heterogeneity of the tumor immune microenvironment in gliomas, the characteristics of patients by the Siglec receptors profile may be useful in verifying corticosteroid therapy and prediction of overall survival.”
Author Response
Please see the attachment.
Author Response File: 
Author Response.pdf
